Professor Lannfelt tilldelas CTAD hederspris för livsgärning inom Alzheimersforskning

BioArctic’s co-founder, Professor Lars Lannfelt, was awarded the Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research at the Clinical Trials in Alzheimer’s Disease (CTAD) congress in Madrid on October 29.

Professor Lannfelt received the award in recognition for his pioneering work in Alzheimer’s disease, specifically his scientific discoveries and contribution to drug development.

Photos: BioArctic

Professor Lannfelt’s groundbreaking research has played a significant role in the scientific progress made in the field over decades, leading to the development of lecanemab, a disease-modifying treatment for early Alzheimer’s disease approved in the U.S., Japan, China, Great Britain and other countries.

“The search for treatments to give hope and help patients and families affected by Alzheimer’s disease is what has driven me throughout my scientific career,” said Professor Lars Lannfelt. “This field or research is in the midst of a paradigm shift driven by the development of treatments such as lecanemab, which has demonstrated meaningful benefits to patients in the large phase 3 trial Clarity AD using gold standard endpoints. Coupled with the introduction of new diagnostic methods, I am convinced that within a number of years, we will not only be able to slow the progression of the disease, but eventually also stop the disease process entirely.”

Professor Lars Lannfelt founded BioArctic together with Pär Gellerfors in 2003 to develop an antibody treatment based on Lannfelt’s groundbreaking discoveries of the role of amyloid-beta protein in Alzheimer’s disease. These discoveries are the basis for lecanemab, an antibody treatment developed in collaboration with the Japanese company Eisai. By binding to specific forms of amyloid-beta, which causes Alzheimer’s disease, lecanemab helps to clear them from the brain, thereby altering the course of the disease.

The 17th annual CTAD international conference brings together 2,200 leading experts in Madrid and online October 29 to November 1 to present and discuss the latest therapeutic advances in Alzheimer’s disease. Scientists from across the globe will present clinical trial results and new therapeutic strategies to treat people experiencing all stages of the disease, including the latest in prevention of Alzheimer’s.